Table 2 Visual acuity changes from baseline and adjusted predictions of visual acuity by linear-mixed model.

From: Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

Characteristics

Total eyes

Typical nAMD

PCV

Ranibizumab

Aflibercept

p value

Ranibizumab

Aflibercept

p value

Ranibizumab

Aflibercept

p value

VA change from baseline (LogMAR letter), mean ± SD

3 months

9.71 ± 15.79

8.50 ± 18.63

0.615*

7.56 ± 18.69

5.02 ± 20.08

0.502*

11.89 ± 11.93

12.53 ± 16.13

0.821*

1 year

6.72 ± 17.52

2.62 ± 24.51

0.182*

1.39 ± 18.45

 − 1.74 ± 24.46

0.472*

11.98 ± 14.95

8.00 ± 23.83

0.334*

2 years

2.05 ± 22.18

 − 0.44 ± 21.95

0.497*

 − 8.07 ± 23.95

 − 5.77 ± 22.82

0.672*

10.85 ± 16.19

6.00 ± 19.30

0.245*

3 years

 − 1.26 ± 21.48

 − 1.79 ± 24.56

0.905*

 − 10.67 ± 23.54

 − 7.18 ± 25.14

0.611*

6.58 ± 16.09

3.86 ± 23.18

0.603*

4 years

 − 2.21 ± 21.55

 − 4.95 ± 26.30

0.583*

 − 11.37 ± 23.42

 − 11.05 ± 23.54

0.963*

6.03 ± 16.01

1.50 ± 29.42

0.492*

Adjusted VA (LogMAR letter), mean ± SD

3 months

62.70 ± 2.09

61.00 ± 2.61

0.610

57.47 ± 3.05

57.17 ± 3.68

0.951

67.99 ± 2.62

65.48 ± 3.38

0.557

1 year

59.60 ± 2.14

55.11 ± 2.65

0.187

51.39 ± 3.14

50.62 ± 3.72

0.873

67.87 ± 2.68

60.57 ± 3.46

0.095

2 years

54.82 ± 2.28

52.36 ± 2.75

0.490

42.60 ± 3.41

45.80 ± 3.87

0.535

66.20 ± 2.79

60.22 ± 3.57

0.187

3 years

49.99 ± 2.43

49.95 ± 3.01

0.992

37.99 ± 3.68

43.49 ± 4.34

0.334

61.01 ± 2.94

57.18 ± 3.82

0.427

4 years

48.64 ± 2.52

46.80 ± 3.13

0.649

36.81 ± 3.79

40.20 ± 4.52

0.566

59.81 ± 3.07

54.21 ± 3.96

0.265

  1. nAMD neovascular age-related macular degeneration, PCV polypoidal choroidal vasculopathy, VA visual acuity, LogMAR Log minimum angle of resolution.
  2. *Independent t-test.
  3. Linear-mixed model.